XML 41 R27.htm IDEA: XBRL DOCUMENT v3.25.4
Impairment loss on goodwill
12 Months Ended
Jun. 30, 2025
Impairment Loss On Goodwill  
Impairment loss on goodwill

 

21. Impairment loss on goodwill

 

Acquisition of Bethesda Medical Pte Ltd and its subsidiary, Oasis Medical Clinic Pte Ltd (“Bethesda Group Acquisition”)

 

On April 30, 2025, the Company completed its acquisition on all of the ordinary shares in the issued and paid-up share capital of Bethesda Medical Pte Ltd, a company incorporated in Singapore. Pursuant to the Sale and Purchase Agreement, the aggregate consideration is S$10,339,950 (US$8,000,000).

 

Following the completion of the acquisition, Bethesda Medical Pte Ltd became a wholly owned indirect subsidiary of Basel Medical Group Ltd. The acquisition was in line with Basel Medical Group’s expansion strategy in Singapore and the broader Southeast Asian healthcare market. By broadening its service offerings and integrating advanced medical solutions, Basel Medical Group is positioning itself as a key player in the region’s evolving healthcare ecosystem.

 

The fair value of identifiable assets and liabilities of Bethesda Group as at the acquisition date were:

 

 Schedule of fair value of identifiable assets and liabilities

   2025 
   S$ 
     
Purchase Consideration   10,339,950 
      
Assets and liabilities recognised as a result of the acquisition:     
Plant and equipment   613,330 
Right-of-use assets   2,906,640 
Deferred tax assets   34,700 
Inventories   388,850 
Trade and other receivables   1,344,120 
Cash and cash equivalents   217,110 
Lease liabilities   (2,906,640)
Deferred tax liabilities   

(118,510

)
Trade and other payables   (2,294,950)
Amount due to director   (193,950)
Net identifiable assets acquired   (9,300)
Add: Goodwill   10,349,250 
Purchase consideration   10,339,950 

 

The acquired business contributed revenue of S$895,362 and net profit of S$206,629 to the Group for the period from 1 May 2025 to 30 June 2025.

 

The purchase consideration of US$8,000,000 was settled in cash in tranches, with US$1,500,000 deferred cash consideration waived off in October 2025.

 

Impairment testing for CGUs containing goodwill

 

For the purposes of impairment testing, the carrying amount of the goodwill has been allocated to the respective clinics based on the revenue generated by each CGUs in the past 12 months as follows:

 

Schedule of impairment testing carrying amount of goodwill

Clinics 

Goodwill allocated

S$

 
Bethesda Medical Clinic (Suntec)   3,721,673 
Bethesda Medical Clinic (Grantral Mall-Macpherson)   1,812,274 
Bethesda Medical Clinic (Toa Payoh)   1,632,637 
Bethesda Medical Clinic (Beach Road)   1,185,408 
Bethesda Medical Clinic (Margaret Drive)   847,978 
Bethesda Medical Clinic (Tampines)   1,149,280 
Total   10,349,250 

 

The recoverable amount of CGUs were based on its value in use, determined by discounting the pre-tax future cash flows to be generated from the continuing use of the CGUs.

 

Key assumptions used in the estimation of value in use were as follows:

 

Schedule of key assumptions used in the estimation of value

Discount rate   5.4%
Terminal growth rate   2%
Revenue growth rate for next five years   5%

 

The discount rate was a pre-tax measure based on the rate of 10-year government bonds issued by the government in the relevant market and in the same currency as the cash flows, adjusted for a risk premium to reflect both the increased risk of investing in equities generally and the systematic risk of the specific CGU.

 

Five years of cash flows were included in the discounted cash flow model.

 

Revenue growth was projected based on expectations of future outcomes taking into account the growth rate of comparable business in the industry.

 

As the new subsidiary’s operation has yet to be turned around, an impairment loss on the goodwill from this investment has been fully recognised in year ended June 30, 2025. Following the impairment loss, the carrying amount of the goodwill is nil.

 

 

Basel Medical Group Ltd. and its Subsidiaries

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For year ended June 30, 2025 and 2024